Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

被引:84
作者
Giles, F [1 ]
Estey, E [1 ]
O'Brien, S [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
D O I
10.1002/cncr.11791
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) linked to N-acetvl-y calicheamicin 1,2-dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AMI,) in a Subset of older patients. Data oil studies in AML with GO-based regimens have been reported rapidly in addition to new observations on the target antigen, CD33. These data indicate promising new areas of investigation with GO, including its application as maintenance therapy in patients with AML and as an induction and/or maintenance agent in patients with acute promyelocytic leukemia;, and they also have highlighted challenges in the development of GO, particularly its association with hepatic venoocclusive disease. In vitro data oil the mechanism of action of GO may be particularly helpful in the design of future clinical studies. Cancer 2003;98: 2095-104. (C) 2003 American Cancer Society.
引用
收藏
页码:2095 / 2104
页数:10
相关论文
共 66 条
[11]   Phase I study of liposomal daunorubicin in patients with acute leukemia [J].
Cortes, J ;
O'Brien, S ;
Estey, E ;
Giles, F ;
Keating, M ;
Kantarjian, H .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) :81-87
[12]   Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia [J].
Cortes, J ;
Tsimberidou, AM ;
Alvarez, R ;
Thomas, D ;
Beran, ML ;
Kantarjian, H ;
Estey, E ;
Giles, FJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (06) :497-500
[13]  
DeAngelo D, 2001, BLOOD, V98, p199B
[14]   EXCLUSIVE PRODUCTION OF BISTRANDED DNA DAMAGE BY CALICHEAMICIN [J].
DEDON, PC ;
SALZBERG, AA ;
XU, JH .
BIOCHEMISTRY, 1993, 32 (14) :3617-3622
[15]   Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse [J].
Dowell, JA ;
Korth-Bradley, J ;
Liu, HJ ;
King, SP ;
Berger, MS .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (11) :1206-1214
[16]   Experience with gemtuzumab ozogamycin ("mylotarg"), and all-trans retinoic acid in untreated acute promyelocytic leukemia [J].
Estey, EH ;
Giles, FJ ;
Beran, M ;
O'Brien, S ;
Pierce, SA ;
Faderl, SH ;
Cortes, JE ;
Kantarjian, HM .
BLOOD, 2002, 99 (11) :4222-4224
[17]   Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside [J].
Estey, EH ;
Thall, PF ;
Giles, FJ ;
Wang, XM ;
Cortes, JE ;
Beran, M ;
Pierce, SA ;
Thomas, DA ;
Kantarjian, HM .
BLOOD, 2002, 99 (12) :4343-4349
[18]   Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome [J].
Giles, F ;
Garcia-Manero, G ;
O'Brien, S ;
Estey, E ;
Kantarjian, H .
ACTA HAEMATOLOGICA, 2002, 108 (03) :164-167
[19]  
Giles F, 2002, HAEMATOLOGICA, V87, P1114
[20]   Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions [J].
Giles, FJ ;
Cortes, JE ;
Halliburton, TA ;
Mallard, SJ ;
Estey, EH ;
Waddelow, TA ;
Lim, JT .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (09) :1182-1185